These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 107337)
1. Ovarian cancer. Effective treatment after alkylating-agent failure. Vogl SE; Greenwald E; Kaplan BH; Moukhtar M; Wollner D JAMA; 1979 May; 241(18):1908-11. PubMed ID: 107337 [TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy of advanced ovarian cancer with hexamethylmelamine, cis-Platinum, and doxorubicin after failure of prior therapy. Vogl SE; Pagano M; Kaplan BH; Einhorn N; Arseneau J; Moukhtar M; Greenwald E Obstet Gynecol; 1980 Nov; 56(5):635-40. PubMed ID: 6776457 [TBL] [Abstract][Full Text] [Related]
3. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Wadler S; Yeap B; Vogl S; Carbone P Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766 [TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients. Brower MS; Coleman M; Pasmantier MW; Silver RT; Mamaril AP; Quiguyan CC Med Pediatr Oncol; 1984; 12(1):17-24. PubMed ID: 6321930 [TBL] [Abstract][Full Text] [Related]
5. The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II). Vogl SE; Berenzweig M; Kaplan BH; Moukhtar M; Bulkin W Cancer Treat Rep; 1979 Feb; 63(2):311-7. PubMed ID: 109202 [TBL] [Abstract][Full Text] [Related]
6. Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy. Vogl SE; Pagano M; Davis TE; Einhorn N; Tunca JC; Kaplan BH; Arseneau JC Cancer Treat Rep; 1982 Jun; 66(6):1285-90. PubMed ID: 6282454 [TBL] [Abstract][Full Text] [Related]
7. cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma. Carmo-Pereira J; Costa FO; Henriques E Cancer Chemother Pharmacol; 1983; 10(2):100-3. PubMed ID: 6403254 [TBL] [Abstract][Full Text] [Related]
8. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens. Pasmantier MW; Coleman M; Silver RT; Ballard WP Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310 [TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma. Piver MS; Lele S; Barlow JJ Cancer Treat Rep; 1981; 65(1-2):149-51. PubMed ID: 6784921 [TBL] [Abstract][Full Text] [Related]
10. Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens. Vogl SE; Pagano M; Kaplan BH; Greenwald E; Arseneau J; Bennett B Cancer; 1983 Jun; 51(11):2024-30. PubMed ID: 6404547 [TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide. Schwartz PE; Lawrence R; Katz M Cancer Treat Rep; 1981; 65(1-2):137-41. PubMed ID: 6261948 [TBL] [Abstract][Full Text] [Related]
12. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer. Bruckner HW; Cohen CJ; Goldberg JD; Kabakow B; Wallach RC; Deppe G; Reisman AZ; Gusberg SB; Holland JF Am J Obstet Gynecol; 1983 Mar; 145(6):653-8. PubMed ID: 6402934 [TBL] [Abstract][Full Text] [Related]
13. Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma. Kane R; Harvey H; Andrews T; Bernath A; Curry S; Dixon R; Gottlieb R; Kukrika M; Lipton A; Mortel R; Ricci J; White D Cancer Treat Rep; 1979 Feb; 63(2):307-9. PubMed ID: 109201 [TBL] [Abstract][Full Text] [Related]
14. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy. Stehman FB; Ehrlich CE; Callangan MF Gynecol Oncol; 1984 Feb; 17(2):189-95. PubMed ID: 6423460 [TBL] [Abstract][Full Text] [Related]
15. Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP). Bruckner HW; Cohen CJ; Deppe G; Kabakow B; Wallach R; Ratner L; Holland JF Gynecol Oncol; 1981 Oct; 12(2 Pt 1):150-3. PubMed ID: 6795095 [No Abstract] [Full Text] [Related]
16. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. Levin L; Simon R; Hryniuk W J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257 [TBL] [Abstract][Full Text] [Related]
17. Alternating multiagent chemotherapy for advanced ovarian cancer. Hernandez E; Rosenshein NB; Villar J; Dillon MB; Ettinger DS; Order SE J Surg Oncol; 1983 Feb; 22(2):87-91. PubMed ID: 6296547 [TBL] [Abstract][Full Text] [Related]
18. Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine. Razis DV; Poulakou E; Petounis A; Papadimitriou G; Kosmides P; Delides G Oncology; 1982; 39(4):205-8. PubMed ID: 6806735 [TBL] [Abstract][Full Text] [Related]
19. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. Pater JL; Carmichael JA; Krepart GV; Fraser RC; Roy M; Kirk ME; Levitt M; Brown LB; Wilson KS; Shelley WE Cancer Treat Rep; 1987 Mar; 71(3):277-81. PubMed ID: 3102056 [TBL] [Abstract][Full Text] [Related]
20. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Heintz AP; van Lent M; Trimbos JB; Bouma J; Vermorken JB J Clin Oncol; 1987 Aug; 5(8):1157-68. PubMed ID: 3114434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]